| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 8647651 | Multiple Sclerosis and Related Disorders | 2017 | 12 Pages | 
Abstract
												During this 30 month study period, re-population rates were significantly delayed post-DMF, irrespective of what subsequent DMT the patients received. Furthermore, no recovery of lymphocyte counts occurred in patients who were started on fingolimod or alemtuzumab after DMF was discontinued; in fact there was a continued decline in all of the cell populations studied.
											Related Topics
												
													Life Sciences
													Biochemistry, Genetics and Molecular Biology
													Genetics
												
											Authors
												Bhupendra O. Khatri, Sergey S. Tarima, Benjamin Essig, Jean Sesing, Tayo Olapo, 
											